March 8, 2010—BG Medicine, Inc. announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.
Under the agreement, Abbott will be responsible for the development of the test in accordance with certain plans and milestones, and BG Medicine and Abbott will collaborate in support of regulatory filings and studies to support the clinical utility of galectin-3 in the management of patients with acute decompensated heart failure... BG Medicine's Press Release -
